Prostate Cancer

TAVT-45, an easy-to-swallow drug that can be suspended in water or juice, is being studied for the treatment of patients with metastatic prostate cancer.

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

As I reflect on cancer survivorship, I notice how important the camraderie with fellow survivors is.

Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy.

Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment.

While my wife has been an amazing caregiver throughout my cancer experience, I realized that it was not fair for her to continually be on the receiving end of all my negative emotions.

Joseph Wood, a patient, and Deborah Wood, Joseph’s wife and caregiver, talk about Joseph’s prostate cancer diagnosis and Deborah explains her role as a caregiver.

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan.

Here is a roundup of cancer treatments that were approved by the FDA in the spring of 2022 that patients may have missed.

Looking back, perhaps a poem could have helped me tell my family about my cancer diagnosis.

Watch Dr. Jeremie Calais, Dr. Tian Zhang, Dr. Landon C. Brown and Jim Rosenfield answer questions about novel agents and strategies during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Landon C. Brown, from Atrium Health Levine Cancer Institute, discuss approaches to hormone therapy, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC.

Despite Latino and Hispanic men being more likely to present with higher-risk prostate cancer, they are less likely to receive treatment for their disease compared to other ethnicities.

After experiencing cancer, I feel a profound sense of empathy for others in tough situations, from the war in Ukraine to COVID-19.

Treatment with androgen deprivation therapy in combination with Zytiga, docetaxel and prednisone improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.

While a higher risk of heart issues was found in older men years after androgen-deprivation therapy, it is unknown if the risk comes from the treatment or other age-related comorbidities.

John Wayne coined the term, “the Big C,” for cancer, but I think it’s time that the capital letter C stands for something better.